2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults
Top Cited Papers
- 1 April 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (Supplement) , i1-i17
Abstract
This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.Keywords
Funding Information
- Infectious Diseases Society of America
- Instituto Nacional do Câncer, Ministério da Saúde
- National Institutes of Health (75N91019D00024)
- Department of Health, State Government of Victoria
This publication has 36 references indexed in Scilit:
- Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare PopulationJAMA Health Forum, 2024
- Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM studyThe Lancet Regional Health - Europe, 2023
- Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort studyThe Lancet Infectious Diseases, 2023
- Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialThe Lancet, 2022
- Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19JAMA Network Open, 2022
- Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialThe Lancet Infectious Diseases, 2022
- Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational studyThe Lancet, 2022
- Time-Dependent COVID-19 Mortality in Patients With CancerJAMA Oncology, 2021
- Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19JAMA Network Open, 2021
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020